RDY SHAREHOLDER ALERT: Dr. Reddy’s Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Dr. Reddy’s Laboratories (“Dr. Reddy’s” or the “Company”) (NYSE: RDY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On July 22, 2026, Dr. Reddy’s reported its first quarter earnings results for fiscal year 2027, revealing an earnings miss and disclosing a ₹2.4 billion provision tied to out-of-spec semaglutide batches. Chief Executive Officer Erez Israeli stated there was “no impact on the product’s existing global regulatory filings” and “no patient-safety impact associated with product already supplied to the market.” On this news, the price of Dr. Reddy’s ADSs fell $1.17 per ADS, or 9%, to close at $11.30 on July 22, 2026.
